Granzyme B; the chalk-mark of a cytotoxic lymphocyte by Waterhouse, Nigel J et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Commentary
Granzyme B; the chalk-mark of a cytotoxic lymphocyte
Nigel J Waterhouse*, Karin A Sedelies and Chris JP Clarke
Address: Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, 8006, Australia
Email: Nigel J Waterhouse* - nigel.waterhouse@petermac.org; Karin A Sedelies - karin.sedelies@petermac.org; 
Chris JP Clarke - chris.clarke@petermac.org
* Corresponding author    
Abstract
During cytotoxic lymphocyte (CL) mediated killing of target cells, granzyme B is released from the
CL into the immune synapse. Recent studies have found that ELISPOT-detection of granzyme B
correlated well with conventional assays for CL mediated killing. In this way, the released granzyme
B can be used to mark the spot where a target cell was murdered. We discuss the benefits and
potential limitations of using this assay to measure CL mediated killing of target cells.
Introduction
Cytotoxic Lymphocytes (CLs) eliminate virally infected
cells or tumour cells either by activating death receptors or
by delivering cytotoxic granule proteins (granule exocyto-
sis) to the target cell [1,2]. The ability of a virus or a
tumour cell to evade detection or survive an attack by CLs
is likely to result in a more aggressive disease. The ability
to measure specific killing of target cells by CLs is there-
fore of great interest to clinicians and researchers alike.
Any assay for CL-induced death involves mixed cultures of
target and effector cells and must include some means of
distinguishing between the two. The current approach is
to measure the release of a label, such as 51Cr or, more
recently calcein-AM [3], that has been preloaded into the
target cells. Radioactivity limits the utility of 51Cr and,
although this type of assay is presumed to measure rup-
ture of the plasma membrane (cell lysis), it is not formally
known what is being measured.
Discussion
Various alternative assays have been developed to assay
CL-induced killing of target cells [4-10], however 51Cr
remains the gold standard. Recently, Shafer-Weaver et al
and others have utilized an interesting strategy aimed at
measuring the functions of effector cells rather than death
of the target cell [9,11]. During granule-mediated killing,
granule enzymes (granzymes) are transferred to the target
cell [2,12]. In the target cell granzyme B, can initiate target
cell death by apoptosis [13,14]. Shafer-Weaver et al., [11]
demonstrated that detection of granzyme B by ELISPOT
correlated well with 51Cr release during antigen specific
target cell death induced by cytotoxic T-lymphocytes and
now report utility of this assay for measuring MHC non-
restricted killing by natural killer cells [15]. Following
incubation of CL with their targets, Shafer-Weaver et al.,
measured granzyme B by ELISPOT and found that the
number of SPOTS correlated well with results obtained by
the 51Cr release assay. Unlike the 51Cr release assay, this
ELISPOT assay measures a specific and well-characterized
event that occurs following target recognition. Assessing
granzyme B by ELISPOT appears superior to other mark-
ers, such as IFNγ, because it assays a molecule that directly
participates in CL mediated killing. Furthermore, the
assay is non-radioactive and under the experimental
parameters reported, it appears possible to detect cytolytic
activity using fewer cells than are required for 51Cr release.
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This assay appears to provide an effective alternative
method for assessing CL-mediated cell death, however,
users should be aware of possible limitations. The assay
measures granzyme B release, not cell death. Frequently,
the two will be closely correlated, but under certain cir-
cumstances using granzyme B release as a marker could
lead either to an under or over estimate of target cell
death. For example, perforin-deficient CLs are unable to
kill targets [16,17], yet they may release granzyme B in the
same way as wild type cells -leading to a false positive
result. Alternatively, cells lacking, or expressing small
amounts of granzyme B may retain the ability to kill tar-
gets by means of other granule components or through
death receptor mediated pathways leading to an underes-
timate of cytotoxic activity [18]. In addition, a CL may
degranulate normally, but certain targets may be inher-
ently resistant to their effects [19]. Thus, to be certain that
degranulation is inducing target cell death, chromium
release assays should be performed alongside the
granzyme B ELISPOT.
The limits of detection of this assay are not clear. It is not
known whether the granzyme B released at a single death-
inducing synapse are sufficient to produce a spot or
whether a CL must degranulate several times, possibly
killing multiple targets, to facilitate detection. Even if one
spot reflects degranulation by one CL and is directly
equivalent to one target cell death, it remains possible that
CLs expressing granzyme B below the level of detection by
ELISPOT may express sufficient granzyme B to kill their
targets. These are difficult issues to address, but the corre-
lation between 51Cr and granzyme B ELISPOT shown
under the conditions used by Shafer-Weaver et al [15] sug-
gests that the levels of detection of the assay are likely to
be broadly equivalent to those required for cell death. It is
however too difficult to directly compare these two assays.
For example, 316 spots were detected in an assay using
50,000 target cells and 10,000 effectors (Table 1). This is
equivalent to 0.6 +/- 0.1 % (as the number of spots must
be related to the number of targets for comparison with
51Cr). Increasing the effectors generated too many spots to
count. Therefore an experiment optimised for 51Cr assay,
(0–70% release as reported in Table 1), will only have a
dynamic range of between 0 and 0.6% using the ELISPOT
assay. In contrast, an assay optimized for ELISPOT is likely
to be off scale in a 51Cr release assay. These data suggest
that a small amount of killing (e.g in a sample with low
level killing) may easily generate a positive result by ELIS-
POT. It is therefore likely that stringent titration of both
effectors and targets over a narrow range will be essential.
Conclusion
The granzyme B-ELISPOT introduces a new assay for
measuring CL mediated toxicity that will have a wide-
spread utility in experimental systems where granzyme B
is present in the effector cell and the target is susceptible
to CL mediated killing. However, no assay used in isola-
tion can be the answer to everyone's prayers and the
granzyme B ELISPOT, like all others, has limitations.
There is no doubt that this assay measures triggering of
degranulation, but it does not directly address the ques-
tion of cell death. Therefore it is likely that the greatest
utility of this assay will be found by using it in combina-
tion with other existing measures of cytotoxic activity. It
may also be extremely valuable as a quick reference to
determine whether killing can occur in an assay with
defined targets and effectors.
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